Ebola virus infection
Conditions
Brief summary
1. Binding anti-EBOV antibody titers I. The course of anti-EBOV immunoglobulin as measured by EBOV ELISA titers during the 24 months following primary vaccination II. Anti-EBOV immunoglobulin as measured by EBOV ELISA titers at 12 and 24 months follow-up, 2. Anti-EBOV neutralizing antibody titers I. The course of anti-EBOV neutralizing antibody titers during the 24 months following primary vaccination II. Anti-EBOV neutralizing titers at 12 and 24 months follow-up
Detailed description
Occurrence of Grade ≥ 3 AE until one month after primary and booster vaccination, Occurrence of SAE throughout the study
Interventions
DRUGErvebo solution for injection Ebola Zaire Vaccine (rVSV∆G-ZEBOV-GP
DRUGlive)
Sponsors
University Medical Center Hamburg-Eppendorf
Eligibility
Sex/Gender
All
Age
18 Years to 64 Years
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Binding anti-EBOV antibody titers I. The course of anti-EBOV immunoglobulin as measured by EBOV ELISA titers during the 24 months following primary vaccination II. Anti-EBOV immunoglobulin as measured by EBOV ELISA titers at 12 and 24 months follow-up, 2. Anti-EBOV neutralizing antibody titers I. The course of anti-EBOV neutralizing antibody titers during the 24 months following primary vaccination II. Anti-EBOV neutralizing titers at 12 and 24 months follow-up | — |
Secondary
| Measure | Time frame |
|---|---|
| Occurrence of Grade ≥ 3 AE until one month after primary and booster vaccination, Occurrence of SAE throughout the study | — |
Countries
Germany
Outcome results
None listed